Business Standard

Elder Pharma appoints Deloitte to restructure business and brands

Company's overall strategy is to position itself further in the growing nutraceuticals segment by launching more products

Press Trust of India  |  New Delhi 

  • ALSO READ

    State Bank of India may slow hiring in next few years Anil Ambani meets Delhi LG Narayana Murthy says non-performing staff will have to go Nissan reduces vehicle prices by up to 6% Private companies, LLP firms can't use 'National' in names

Elder Pharmaceuticals has appointed consulting firm for restructuring the company and its brands including 'Eldervit' following the sale of its formulation business to Torrent Pharmaceuticals for Rs 2,004 crore.

The company's overall strategy is to focus on its remaining brands including Eldervit and Somazina and position itself further in the growing nutraceuticals segment by launching more products, said in a statement today.

As per the deal, major chunk of Elder Pharma's employees will be joining Ahmedabad-based Torrent Pharmaceuticals after March 31 and would need an organisational restructuring.

It will be part of Deloitte's consultancy job, the statement added.

Besides, the company is also planning to concentrate and build on its domestic business of anti-infectives, strengthen its in-license portfolio and grow its business in the UK and Europe.

At the same time, it would explore the possibility of entering new therapeutics areas, said Elder Pharma.

On December 13, 2013 the Mumbai-based firm had announced it would sell its branded formulation business, comprising 30 brands, to Torrent Pharmaceuticals for Rs 2,004 crore.

The deal, which has been approved by the boards of both companies, is expected to close in the first half of 2014.

"Given the strategy to focus on key brands and key areas, and to re-structure and re-strategise the brands and people, Elder Pharma would easily increase its revenues and profitability," the company's CMD Alok Saxena said.

Shares of Elder Pharma were trading at Rs 189.75 apiece, down 0.26 per cent from its previous close, during afternoon trade on the BSE.

RECOMMENDED FOR YOU

Elder Pharma appoints Deloitte to restructure business and brands

Company's overall strategy is to position itself further in the growing nutraceuticals segment by launching more products

Elder Pharmaceuticals has appointed consulting firm Deloitte for restructuring the company and its brands including 'Eldervit' following the sale of its formulation business to Torrent Pharmaceuticals for Rs 2,004 crore. The company's overall strategy is to focus on its remaining brands including Eldervit and Somazina and position itself further in the growing nutraceuticals segment by launching more products, Elder Pharma said in a statement today. As per the deal, major chunk of Elder Pharma's employees will be joining Ahmedabad-based Torrent Pharmaceuticals after March 31 and would need an organisational restructuring. It will be part of Deloitte's consultancy job, the statement added. Besides, the company is also planning to concentrate and build on its domestic business of anti-infectives, strengthen its in-license portfolio and grow its business in the UK and Europe. At the same time, it would explore the possibility of entering new therapeutics areas, said Elder ... Elder Pharmaceuticals has appointed consulting firm for restructuring the company and its brands including 'Eldervit' following the sale of its formulation business to Torrent Pharmaceuticals for Rs 2,004 crore.

The company's overall strategy is to focus on its remaining brands including Eldervit and Somazina and position itself further in the growing nutraceuticals segment by launching more products, said in a statement today.

As per the deal, major chunk of Elder Pharma's employees will be joining Ahmedabad-based Torrent Pharmaceuticals after March 31 and would need an organisational restructuring.

It will be part of Deloitte's consultancy job, the statement added.

Besides, the company is also planning to concentrate and build on its domestic business of anti-infectives, strengthen its in-license portfolio and grow its business in the UK and Europe.

At the same time, it would explore the possibility of entering new therapeutics areas, said Elder Pharma.

On December 13, 2013 the Mumbai-based firm had announced it would sell its branded formulation business, comprising 30 brands, to Torrent Pharmaceuticals for Rs 2,004 crore.

The deal, which has been approved by the boards of both companies, is expected to close in the first half of 2014.

"Given the strategy to focus on key brands and key areas, and to re-structure and re-strategise the brands and people, Elder Pharma would easily increase its revenues and profitability," the company's CMD Alok Saxena said.

Shares of Elder Pharma were trading at Rs 189.75 apiece, down 0.26 per cent from its previous close, during afternoon trade on the BSE.
image
Advertisement